GMP Software: Quality Management for Good Manufacturing Practice Compliance

All seven GMP pillars. One validated platform.

GMP Software: A cGMP Compliance System That Manages Every Good Manufacturing Practice Requirement in a Single Validated Platform

Quality professionals in pharmaceutical manufacturing frequently search for GMP software rather than pharmaceutical QMS software, and the distinction is meaningful. The QMS frame suggests a quality management discipline. The GMP frame suggests a manufacturing compliance obligation. Both are accurate, but a manufacturing quality professional whose primary accountability is FDA inspection readiness thinks first about cGMP compliance — the specific manufacturing standards that Current Good Manufacturing Practice requires — and whether their software systems collectively manage every GMP-required quality process.

The answer that this page provides is straightforward: GMP compliance requires a quality management system, and eLeaP is a GMP software system because it manages every GMP-required quality process in a single validated platform. This is not a QMS with GMP capability added. It is a system built around the seven compliance pillars that cGMP requires every pharmaceutical manufacturer to maintain — trained personnel, qualified facilities and equipment, validated processes, controlled documentation, complete records, investigated test results, and investigated complaints.

Greenlight Guru holds some GMP content positions through their medical device regulatory glossary. MasterControl and ComplianceQuest hold partial positions on GMP software terms. None of them is purpose-built for the pharmaceutical GMP compliance obligation the way eLeaP is. This page covers each of the seven GMP pillars, what cGMP requires for each, and how eLeaP’s GMP software addresses it.

GMP vs. cGMP: Why the ‘c’ Matters for Software Selection

Good Manufacturing Practice is the global standard for pharmaceutical manufacturing quality. Current Good Manufacturing Practice is the FDA’s regulatory term, and the ‘c’ is not a formality. It reflects FDA’s position that compliance with GMP standards must reflect current state-of-the-art manufacturing technology and quality system practices — what was acceptable in 1978 when the regulation was promulgated may not be acceptable today. FDA regularly issues guidance documents and warning letters that clarify what current practice means for specific GMP areas, and those clarifications evolve over time.

For software selection, the cGMP distinction matters in one specific way: a cGMP compliance software system must be capable of supporting current quality system practices, not the practices of a decade ago. An electronic batch record system that does not support real-time exception capture is not the current practice. A CAPA system that cannot enforce effectiveness verification is not a current practice. A training system that cannot link training completion records to specific document versions is not current practice. FDA’s increasing emphasis on data integrity, electronic records, and computerised system validation in recent inspection cycles reflects the ‘current’ standard moving toward more rigorous electronic quality system requirements. eLeaP’s cGMP compliance software is designed against the current standard.

The Seven GMP Compliance Pillars: What cGMP Requires and How eLeaP Addresses Each

21 CFR Parts 210 and 211 establish the cGMP requirements for finished pharmaceutical products. The requirements are organised into seven operational pillars that a GMP software system must support. Each pillar has specific regulatory citations and specific failure modes that generate FDA 483 observations and warning letter citations.

Pillar 1: Trained and Qualified Personnel — 21 CFR Part 211.68

21 CFR Part 211.68 requires that personnel engaged in the manufacture, processing, packing, or holding of drug products have the education, training, and experience to enable them to perform their assigned functions. Training must be documented. FDA investigators reviewing training compliance during inspections expect records that demonstrate each person performing a GMP function is trained on the current version of the procedures governing that function, not a prior version that was superseded six months ago.

eLeaP GMP software addresses this pillar through its integrated LMS. The training matrix defines required training by role. When an SOP is revised and a new version becomes effective, eLeaP automatically identifies every role assigned to that procedure and creates retraining assignments for every employee in those roles. Completion records carry the specific document version number. An inspector asking whether a production operator is trained on the current version of a validated cleaning procedure receives a single-query response showing the operator’s training record, the document version, the completion date, and the assessment score. The training gap that generates observation findings — operators working from superseded procedures — is structurally closed rather than procedurally managed.

Pillar 2: Qualified Facilities and Equipment — 21 CFR Parts 211.63 and 211.68

21 CFR Part 211.63 requires that equipment used in manufacturing, processing, packing, or holding of drug products be of appropriate design, adequate size, and suitably located. Part 211.68 requires that automatic, mechanical, and electronic equipment used in manufacturing be routinely calibrated, inspected, or checked according to written procedures. Equipment qualification — Installation Qualification, Operational Qualification, and Performance Qualification — is the documented evidence that equipment is suitable for its intended use in GMP manufacturing.

eLeaP manages equipment qualification and calibration records within the quality system. IQ, OQ, and PQ protocols and reports link to the equipment record. Requalification triggers — scheduled interval, change control event, or deviation event involving the equipment — generate tasks within the system. Equipment out of calibration or with an expired qualification interval generates a status flag that prevents the equipment from being used in GMP production activities until the qualification or calibration is renewed and documented. When a process change affects a qualified piece of equipment, the change control record identifies the requalification requirement and tracks it to completion.

Pillar 3: Validated Processes — 21 CFR Part 211.100 and FDA Process Validation Guidance

21 CFR Part 211.100 requires that written procedures be established and followed for production and process controls. FDA’s 2011 process validation guidance establishes a three-stage validation lifecycle: Stage 1 process design, Stage 2 process qualification, and Stage 3 continued process verification. Each stage has documentation requirements that a GMP software system must organise and maintain. Stage 3 continued process verification requires ongoing analysis of process performance data to confirm the process remains in a state of control, which requires the quality system to aggregate batch production data and surface trends.

eLeaP manages process validation documentation within the product record structure. Validation protocols and reports for each stage link to the production process they validate. Changes to validated processes route through the change control workflow, which includes a validated state impact assessment and generates revalidation requirements where the assessment indicates the change falls outside the established design space. Stage 3 continued process verification data — drawing from batch records, in-process testing records, and deviation records in the integrated system — is available for trend analysis and annual product review without manual data compilation from separate systems.

Pillar 4: Controlled Documentation — 21 CFR Part 211.100 and Part 211.186

21 CFR Part 211.100 requires that written procedures be established, followed, and documented for the manufacture and process control activities governing drug product production. 21 CFR Part 211.186 requires that master production and control records, prepared for each drug product, be accurate reproductions of the approved master formula and that they be signed by one person and independently checked by a second. Document control in GMP manufacturing is not a file management problem. It is a compliance control: current procedures must be accessible to personnel performing the activities they govern, prior versions must be archived but not accessible as current, and changes must be approved and implemented through a controlled process.

eLeaP’s document control module manages the full SOP and master record lifecycle with 21 CFR Part 11-compliant electronic signatures on authoring, review, and approval. The effective date triggers automatic supersession of the prior version and automatic distribution to authorised roles. Personnel cannot access a prior version of a procedure through the active document library once a new version is effective. Master production records are version-controlled within the batch record template structure, so a batch initiated on any given date is linked to the master record version that was effective on that date.

Pillar 5: Complete and Retrievable Records — 21 CFR Part 211.188 and Part 211.192

21 CFR Part 211.188 requires that batch production and control records be prepared for each batch and include complete documentation of every production step. 21 CFR Part 211.192 requires that completed batch records be reviewed and approved by the quality control unit before batch release, and that any unexplained discrepancy be thoroughly investigated. Part 211.180 requires that all records be retained for not less than one year after the expiry date of the batch and be readily available for review by the FDA.

eLeaP’s electronic batch record system captures batch execution with step-by-step documentation, operator identity, timestamps, in-process test results, and deviation records linked directly from within the batch record. Automatic calculation of yields, concentrations, and material reconciliation reduces transcription error and manual calculation risk. The batch record review presents the complete execution record, all in-process test results, and all linked deviation records in a single structured view for the quality control reviewer. Batch records are indexed and retrievable by batch number, lot number, product, and date in seconds — the retrieval speed that FDA inspection readiness requires.

Pillar 6: Investigated Test Results — 21 CFR Part 211.192 OOS Investigations

21 CFR Part 211.192 requires that any failure of a batch or any of its components to meet specifications be thoroughly investigated, whether or not the batch has already been distributed. FDA’s guidance on out-of-specification laboratory results establishes a two-phase investigation structure: Phase 1 laboratory investigation for an assignable laboratory cause, and Phase 2 full-scale investigation if no laboratory cause is found. The investigation must extend to other batches of the same drug product and any other product that may have been associated with the specific failure.

eLeaP’s OOS investigation workflow enforces the two-phase FDA guidance structure. Phase 1 fields capture the laboratory review with supervisor sign-off. Advancement to Phase 2 result invalidation requires documented Phase 1 completion without an assignable laboratory cause. Phase 2 records connect to the batch record for the affected lot, to any associated deviation records, and to the CAPA if systemic corrective action is required. OOS investigations that exceed defined turnaround time targets generate escalation notifications to quality management. Investigation trends by test method, analyst, and product are available for the management review data package.

Pillar 7: Investigated Complaints — 21 CFR Part 211.198

21 CFR Part 211.198 requires written procedures for handling written and oral complaints regarding a drug product. Every complaint involving a possible failure to meet specifications must be investigated. The investigation must cover other lots of the same product and any other product potentially affected. Complaints are one of the most inspection-sensitive areas of the pharmaceutical quality system because they represent a product reaching the patient, and the quality system’s response to patient experience reports is a direct indicator of product safety commitment.

eLeaP’s complaint management module captures drug product complaints with all mandatory Part 211.198 fields required at intake. The investigation workflow routes complaints to the quality control unit for the determination of whether the complaint represents a possible specification failure requiring investigation. Lot extension evaluation — determining whether the complaint indicates a batch-level or process-level quality failure affecting other distributed lots — is a required workflow stage for complaints involving possible product defects. CAPA is initiated directly from within the complaint investigation record when the investigation confirms a quality system failure. Complaint trending surfaces patterns by product, lot family, and complaint type for proactive quality management.

GMP Training Management: The Regulatory Requirement That Connects the Quality System to the Workforce

GMP training under 21 CFR Part 211.68 is not a human resources function. It is a quality system function with direct inspection consequences. FDA investigators assess training compliance as a routine component of pharmaceutical manufacturing inspections, and training record deficiencies — records that reference superseded procedure versions, training programs that lack effectiveness evaluation, role changes that were not reflected in updated training requirements — generate observations that affect inspection outcomes and CAPA obligations.

The most common GMP training gap is not a missing training program. It is the interval between a procedure revision becoming effective and the workforce being trained on it. In a pharmaceutical manufacturing facility that revises dozens of procedures per year, each revision creates a training obligation for every employee whose job function is governed by that procedure. Managing that obligation manually — identifying affected employees, creating training assignments, tracking completions, confirming that implementation occurred before personnel worked under the new procedure — is an administrative burden that produces gaps proportional to the volume of procedure revisions and the size of the workforce.

eLeaP’s cGMP compliance software eliminates that administrative burden through the integrated QMS and LMS architecture. Every procedure revision that becomes effective in the document control system automatically generates training assignments for all affected roles. The training assignment carries the procedure version number. The completion record links to that specific version. No manual action is required between a procedure being approved and the training assignments being created. No reconciliation is required between the training record and the document version history to demonstrate currency.

For GMP training effectiveness evaluation, eLeaP supports configurable assessment methods by training type. Knowledge assessments for procedure training capture a pass or fail status with a score. Observed competency assessments for hands-on procedures capture the evaluator’s identity and the observation date. Periodic retraining intervals are configurable by procedure category — annual retraining for standard SOPs, more frequent retraining for high-risk or high-frequency procedures. Approaching retraining intervals generates notifications to the employee and supervisor before the interval lapses, keeping the training record current without an annual audit scramble.

GMP Software vs. Generic QMS: Why the Frame Matters for Pharma Buyers

A generic quality management system manages quality records. A GMP software system manages the specific quality records that GMP regulations require, in the workflow structures that GMP regulations specify, with the documentation standards that FDA investigators apply during inspections. The difference is not theoretical — it is visible in what the system captures by default, what the system requires before records can advance, and what the system can produce immediately when an inspector arrives.

A generic QMS produces a deviation record. A GMP software system produces a deviation record that links to the batch in which the deviation occurred, routes to the quality unit for investigation, requires a root cause determination before the investigation can close, and generates a CAPA if the root cause indicates a systemic quality system failure. The structural difference between those two outcomes is the difference between a documentation system and a compliance system.

eLeaP is a GMP software system in the compliance sense. Every module was designed around the specific GMP regulatory requirements of pharmaceutical manufacturing: batch records structured around 21 CFR Part 211.188, OOS investigations structured around FDA’s two-phase guidance, CAPA structured around ICH Q10 Section 3.4 effectiveness verification, and training structured around 21 CFR Part 211.68 procedure version currency. The GMP compliance architecture is not a configuration layer applied to a generic workflow tool. It is the foundational design of the platform.

Evaluating GMP Software: Five Questions That Reveal Compliance Depth

GMP software evaluation should test compliance architecture, not feature presence. The questions below apply to each of the major GMP software contenders in this keyword cluster.

eLeaP’s answers to all five questions are yes. The GMP software demo covers the batch record execution workflow with exception flag and automatic deviation creation, the OOS investigation two-phase structure, the procedure revision-to-training assignment sequence, and the CAPA effectiveness gate — configured for the buyer’s drug product type and manufacturing context. Request a scoped GMP software demo at eleapsoftware.com.

Related resources: